中文

Immunocore (IMCR)

Biotech

Close on Nov 11, 2026 (from our latest Long View update): $31.65

Market value
$1.6Bat the Nov 11 close
Revenue growth
+13%12 months to Sep 30, 2026 (10-Q)
FCF margin
−4%12 months to Sep 30, 2026 (10-Q)
Net cash
$507Mat Sep 30, 2026
Worst fall since listing
−67.5%Feb 7, 2024 to Apr 8, 2025; not back to that high (−64.7% now)

About the company

Latest

  • Up 9.1% Quarterly
    Immunocore Q3 2026: sales dip after Q2 stocking; key melanoma trial data slips to Q2 2027

The Long View

Immunocore listed on Nasdaq in 2021 and won approval for Kimmtrak in 2022, the first drug its platform produced.

▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash

Updated Nov 12, 2026

Read the Long View →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

Long-term fundamentals

Annual results for Immunocore, FY2021–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $36M in FY2021 to $400M in FY2025. Free cash flow was positive in 1 of the 5 years shown; FY2025: −$15M. Each year's figures are in the table below. −$200M$0$200M$400M$600M ’21 ’22 ’23 ’24 ’25

Revenue went from $36M in FY2021 to $400M in FY2025.

Free cash flow was positive in 1 of the 5 years shown; FY2025: −$15M.

Margins

Operating margin was −11% in FY2025, vs −479% in FY2021. Gross margin was 99% in FY2025, vs 100% in FY2021. Each year's figures are in the table below. −600%−400%−200%0%200% ’21’22’23’24’25

Operating margin was −11% in FY2025, vs −479% in FY2021.

Gross margin was 99% in FY2025, vs 100% in FY2021.

Diluted share count

The diluted share count rose 18% from FY2021 to FY2025, to 50M. Each year's figures are in the table below. 42M44M46M48M50M52M ’21’22’23’24’25

The diluted share count rose 18% from FY2021 to FY2025, to 50M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$400M99%−11%−$36M−$11M$4M−$15M
FY2024$310M99%−23%−$51M$26M$5M$21M
FY2023$249M100%−24%−$55M$3M$5M−$2M
FY2022$174M99%−30%−$53M−$49M$2M−$51M
FY2021$36M100%−479%−$180M−$143M$1M−$144M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY202550M$864M$393M$38M——
FY202450M$820M$391M$34M——
FY202349M$443M$48M$32M——
FY202246M$402M$48M$33M——
FY202142M$321M—$49M——

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 6, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

  • Debt is the carrying value of borrowings on the balance sheet, tagged LongTermNotesAndLoans; FY2021 is not available in this data.
  • Gross profit is revenue minus cost of revenue (the 10-K does not report a gross profit line).
  • Cash for FY2021 includes restricted cash (the only cash total tagged).

Returns by year

YearIMCRS&P 500
2019—+31.5%
2020—+18.4%
2021−20.7%†+28.7%
2022+66.7%−18.1%
2023+19.7%+26.3%
2024−56.8%+25.0%
2025+17.7%+17.9%
2026 to date−23.3%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. † From the first close after listing (Feb 5, 2021); "—" is before listing. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about Immunocore

How does Immunocore make money?
All of its revenue comes from Kimmtrak (tebentafusp), approved in 2022 for metastatic uveal melanoma in patients with the tissue type HLA-A*02:01. Net sales were $400.0M in 2025: 64% in the US, 33% in Europe and 3% elsewhere (our calculation). More in the Long View →
How do Immunocore's medicines work?
They are bispecific T-cell receptor medicines from its ImmTAX platform. Its cancer drugs recognise fragments of proteins from inside tumour cells that are displayed on the cell surface, and redirect the patient's own T cells to kill those cells. More in the Long View →
What could widen Immunocore's business?
It is running three Phase 3 trials in melanoma (TEBE-AM, PRISM-MEL-301 and ATOM) and earlier programmes in other cancers, HIV and autoimmune disease. More in the Long View →
Who pays for Kimmtrak?
Kimmtrak is sold mainly through specialty distributors in the US and to hospitals and distributors in Europe; four unnamed customers each bought 17–23% of 2025 net product sales. The money ultimately comes from US government programmes and private insurers and from European national health systems. More in the Long View →
Which outside manufacturers does Immunocore rely on?
AGC Biologics in Denmark and Simtra Biopharma Solutions in Germany manufacture Kimmtrak. Deutsche Post DHL Group handles storage, distribution, packaging and labelling in the Netherlands. More in the Long View →
What's coming up for Immunocore's pipeline in the next 12 months?
Immunocore expects topline overall survival data from its Phase 3 TEBE-AM trial in the second quarter of 2027; the trial is event-driven. It plans to file a clinical trial application (CTA) or investigational new drug (IND) application for IMC-U120AI before the end of 2026, and to start DUET-UVEAL, a randomized Phase 2/3 trial, for which it gave no date. As of Nov 6, 2026 More in the Long View →

Disclosure: one or more of our editors own shares of Immunocore (IMCR) as a long-term investment.